| Full title: | A randomised phase II study comparing Capecitabine with Capecitabine and oral Cyclophosphamide in patients with advanced breast cancer. |
| Cancer type: | Breast |
| Status: | Closed (82 participants recruited) |
|
Brief description:
|
This trial is a phase II study which is comparing two chemotherapy treatments for advanced breast cancer – capecitabine and capecitabine with cyclophosphamide. Both drugs being used are taken by mouth, and are both already used to treat breast cancer, but they are not usually used together. |
| Sites: |
· Auckland · Waikato · Palmerston North · Wellington · Nelson · Christchurch · Dunedin |
| Lead Investigator: | Professor Vernon Harvey |
| Contact: | Sarah Benge (s.benge@auckland.ac.nz) |
| Sponsor: | University of Auckland |
| Funder: | Roche |
| Trial Registry reference: |
ACTRN12605000377639 (click for more details) ISRCTN68662102 (click for more details) |
| Ethics number: | AKY/04/02/001 |
| Publications: | Harvey, V. J., Sharples, K. J., Isaacs, R. J., Jameson, M. B., Jeffery, G. M., McLaren, B. R., Pollard, S., Riley, G. A., Simpson, A. B., Hinder, V.A. Scott, J.N., Dzhelali, M.V., Findlay, M. P. (2013). A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer – Cyclox II. Ann Oncol, 24 (7), 1828-1834. doi:10.1093/annonc/mdt065 |